Oncolys BioPharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 4588?
Owner Type	Number of Shares	Ownership Percentage
Public Companies	845,800	3.41%
Individual Insiders	981,200	3.95%
Institutions	1,467,728	5.91%
General Public	21,528,134	86.7%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.4%.

Top Shareholders

Top 18 shareholders own 19.68% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
3.59%	Rakuten Investment Management, Inc.	890,600	JP¥454.2m	0%	0.2%
2.93%	Astellas Pharma Inc.	727,200	JP¥370.9m	0%	no data
2.8%	Central Tanshi Co., Ltd., Asset Management Arm	696,200	JP¥355.1m	0%	1.02%
2.22%	SBI Holdings Inc., Asset Management Arm	551,114	JP¥281.1m	0%	0.09%
2.01%	Yasuo Urata	498,900	JP¥254.4m	0%	no data
1.63%	Evolution Capital Management LLC	405,000	JP¥206.5m	-9.19%	1.42%
0.88%	Hitoshi Nakanishi	219,000	JP¥111.7m	0%	no data
0.83%	Japan Securities Finance Co. Ltd., Asset Management Arm	205,400	JP¥104.8m	0%	0.01%
0.52%	Taizo Kawabata	128,700	JP¥65.6m	0%	no data
0.48%	Asahi Intecc Co., Ltd.	118,600	JP¥60.5m	0%	no data
0.46%	Yasunari Kashihara	115,000	JP¥58.6m	0%	no data
0.44%	Simplex Asset Management Co., Ltd.	109,100	JP¥55.6m	1.39%	0.03%
0.4%	au Kabucom Securities Co., Ltd., Asset Management Arm	100,500	JP¥51.3m	0%	0.25%
0.4%	Matsui Securities Co. Ltd., Asset Management Arm	100,000	JP¥51.0m	0%	0.21%
0.073%	Keiji Yoshimura	18,000	JP¥9.2m	0%	no data
0.0048%	Sumitomo Mitsui Financial Group Inc., Asset Management Arm	1,200	JP¥611.5k	0%	no data
0.004%	Shiro Ohki	1,000	JP¥510.2k	0%	no data
0.0024%	Katsufusa Tachiya	600	JP¥306.4k	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 19:51
End of Day Share Price	2024/12/26 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oncolys BioPharma Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kiyokazu Yamazaki	Ichiyoshi Research Institute Inc.